1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. News
  7. Summary
    VLA   FR0004056851


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Valneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late

01/19/2022 | 05:18am EDT

By Julien Maron and Joshua Kirby

Shares in French biotechnology company Valneva SE sank Wednesday as concerns mounted over the commercial prospects of its coronavirus vaccine candidate, VLA2001.

At 0944 GMT, shares were down 12% at EUR13.82.

Vaccine scarcity could turn into a vaccine surplus as the pandemic becomes endemic, a situation in which only vulnerable people may be eligible for vaccination, Stifel analyst Max Herrmann said. In this context, Valneva could struggle to obtain new contracts, he said.

The Omicron variant has meanwhile shown that vaccines don't prevent record numbers of daily new transmissions, Mohamed Kaabouni of Portzamparc said. The first pharmaceutical players to introduce vaccines--Pfizer Inc., Moderna Inc., Johnson & Johnson and, most recently, Novavax Inc.--have saturated the market in developed countries, Mr. Kaabouni added.

"It seems investors fear that those vaccines that have yet to get the nod from regulators, like Valneva's, risk arriving once the horse has already bolted," he said.

Valneva earlier this month confirmed that it expected to receive potential approval for VAL2001 from regulators in the European Union, the U.K. and Bahrain in the first quarter of the year.

This story was translated in whole or in part from a French-language version initially published by L'Agefi-Dow Jones.

Write to Julien Maron at jmarion@agefi.fr and to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

(END) Dow Jones Newswires

01-19-22 0518ET

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.75% 176.98 Delayed Quote.1.68%
MODERNA, INC. -4.97% 136.25 Delayed Quote.-46.35%
NOVAVAX, INC. -8.57% 53.42 Delayed Quote.-62.66%
PFIZER, INC. 3.59% 52.47 Delayed Quote.-11.14%
VALNEVA SE 1.45% 11.88 Real-time Quote.-51.51%
All news about VALNEVA SE
05/20VALNEVA : EMA Accepts Filing of Marketing Authorization Application for Valneva's Inactiva..
05/20EMA Accepts Filing of Marketing Authorization Application for Valneva's Inactivated COV..
05/20EMA accepts filing of marketing authorization application for Valneva's inactivated COV..
05/19European shares lower as retailers, food and beverage stocks lead falls
05/19EU Accepts Valneva's COVID-19 Jab Marketing Authorization Application
05/19EU's drug regulator accepts Valneva's COVID-19 vaccine marketing authorization filing
05/19EMA Accepts Filing of Marketing Authorization Application for Valneva's Inactivated COV..
05/19EMA Accepts Filing of Marketing Authorization Application for Valneva's Inactivated COV..
05/17Valneva Receives Notice of European Commission's Intent to Terminate COVID-19 Vaccine P..
05/17What you need to know about the coronavirus right now
More news
Analyst Recommendations on VALNEVA SE
More recommendations
Sales 2022 381 M 401 M 401 M
Net income 2022 -28,5 M -30,1 M -30,1 M
Net cash 2022 213 M 225 M 225 M
P/E ratio 2022 -34,9x
Yield 2022 -
Capitalization 1 280 M 1 351 M 1 351 M
EV / Sales 2022 2,80x
EV / Sales 2023 1,36x
Nbr of Employees 762
Free-Float 73,9%
Duration : Period :
Valneva SE Technical Analysis Chart | VLA | FR0004056851 | MarketScreener
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 11,88 €
Average target price 20,08 €
Spread / Average Target 69,0%
EPS Revisions
Managers and Directors
Thomas Lingelbach President & Chief Executive Officer
Franck Charles Marie Grimaud Director General & Chief Business Officer
Peter Buhler Chief Financial Officer & Director
Frédéric Grimaud Chairman-Supervisory Board
Michael Möhlen Vice President-Technical Development
Sector and Competitors
1st jan.Capi. (M$)
VALNEVA SE-51.51%1 351
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704